ItalianoNasso, Cecilia
Dettaglio
Nasso, Cecilia
Pubblicazioni
Risultati 1 - 11 di 11 (tempo di esecuzione: 0.002 secondi).
| Titolo | Data di pubblicazione | Autore(i) | |
|---|---|---|---|
| 1 | Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. | 2019 | Omarini, Claudia; Piacentini, Federico; Sperduti, Isabella; Barbolini, Monica; Isca, Chrystel; Nasso, Cecilia; Toss, Angela; D'Onofrio, Raffaella; Cortesi, Laura; Barbieri, Elena; Cascinu, Stefano; Moscetti, Luca |
| 2 | Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. | 2019 | Palumbo, Patrizia; Draisci, Stefano; Barbolini, Monica; Nasso, Cecilia; Isca, Chrystel; Bocconi, Alessandro; Balduzzi, Sara; Pecchi, Annarita; Galetti, Silvia; Torricelli, Pietro; Piacentini, Federico; Moscetti, Luca; Cascinu, Stefano; Omarini, Claudia |
| 3 | Long progression-free survival with cabozantinib in a heavily pretreated patient with metastatic renal cell carcinoma: a case report | 2021 | Nasso, C.; Sabbatini, R.; Baldessari, C.; Dominici, M.; Vitale, M. G. |
| 4 | Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus | 2018 | Omarini, Claudia; Filieri, Maria Elisabetta; Bettelli, Stefania Raffaella; Manfredini, Samantha; Kaleci, Shaniko; Caprera, Cecilia; Nasso, Cecilia; Barbolini, Monica; Guaitoli, Giorgia; Moscetti, Luca; Maiorana, Antonino; Conte, Pierfranco; Cascinu, Stefano; Piacentini, Federico |
| 5 | Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. | 2019 | Omarini, C; Palumbo, P; Pecchi, A; Draisci, S; Balduzzi, S; Nasso, C; Barbolini, M; Isca, C; Bocconi, A; Moscetti, L; Galetti, S; Tazzioli, G; Torricelli, P; Cascinu, S; Piacentini, F. |
| 6 | Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. | 2020 | Nasso, C.; Barbolini, M.; Isca, C.; D'onofrio, R.; Cortesi, G.; Dominici, M.; Piacentini, F.; Omarini, C. |
| 7 | PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis | 2020 | D'Onofrio, R.; Omarini, C.; Barbolini, M.; Nasso, C.; Isca, C.; Dominici, M.; Piacentini, F. |
| 8 | Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe | 2021 | Moscetti, L.; Sperduti, I.; Frassoldati, A.; Musolino, A.; Nasso, C.; Toss, A.; Omarini, C.; Dominici, M.; Piacentini, F. |
| 9 | TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis | 2021 | Omarini, Claudia; Piacentini, Federico; Sperduti, Isabella; Cerma, Krisida; Barbolini, Monica; Canino, Fabio; Nasso, Cecilia; Dominici, Massimo; Moscetti, Luca |
| 10 | Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis | 2021 | Moscetti, Luca; Omarini, Claudia; Sperduti, Isabella; Canino, Fabio; Barbolini, Monica; Nasso, Cecilia; Toss, Angela; Dominici, Massimo; Piacentini, Federico |
| 11 | Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era | 2021 | Toss, A; Isca, C; Venturelli, M; Nasso, C; Ficarra, G; Bellelli, V; Armocida, C; Barbieri, E; Cortesi, L; Moscetti, L; Piacentini, F; Omarini, C; Andreotti, A; Gambini, A; Battista, R; Dominici, M; Tazzioli, G |
Copyright © 2022